A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects

Abstract

Tbo-filgrastim is a recombinant human granulocyte colony-stimulating factor approved by the US Food and Drug Administration to reduce the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. We assessed the effect of tbo… (More)
DOI: 10.2147/DDDT.S81799

Topics

8 Figures and Tables

Slides referencing similar topics